Form S-3 BIORA THERAPEUTICS, INC.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biora Therapeutics (BIOR) PT Lowered to $15 at H.C. Wainwright
April 9, 2024 6:37 AM EDTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Biora Therapeutics (NASDAQ: BIOR) to $15.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "Initial SAD data reaffirm NaviCap's MoA and fruther de-risk upcoming clinical readouts. During 2023, Biora made significant headway advancing its two leading drug delivery devices: Biojet and NaviCap. The BioJet made considerable progress in preclinical evaluations; data readouts using BioJet is anticipated throughout 2024. Moreover, NaviCap... More
